Bright Brothers (526731)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹133.55 provides some support; P/B of 1.17 is not excessive.
• ROCE of 16.18% suggests decent operational capital efficiency.
• Sales growth of 5.38% is positive, showing the top line is not collapsing.
• Dividend yield of 1.21% offers a small income cushion.
• Small market cap of ₹89 Cr leaves room for potential operational improvement to move the needle.

Concerns

• Latest quarter net loss of ₹1 Cr and profit growth of -245% show current earnings distress.
• Piotroski F-Score of 4/9 indicates weak fundamental health.
• Current price is below the stated 52-week low of ₹185.35, suggesting negative momentum or a value trap.
• PEG of 3.88 and P/E of 20.85 look unattractive for only 5.38% sales growth.

AI Analysis

At ₹156.60, Bright Brothers is a small industrial plastic player with a market cap of just ₹89 Cr. The first thing I notice is that the market is paying 20.85 times earnings and 1.17 times book value for a business whose latest quarter lost ₹1 Cr. Graham would ask: what am I really buying? Book value of ₹133.55 gives some floor, but discipline requires a margin of safety. The reported profit growth of -245% is a warning sign; although the trailing P/E is positive, the quarterly loss tells me the earnings power is fragile. ROCE of 16.18% is above ROE of 9.58%, but without debt/equity data I cannot judge how much financial leverage or tax drag is behind that gap. Sales growth of 5.38% is pedestrian, not enough to justify a PEG of 3.88. The Piotroski F-score of 4 out of 9 is below what I like to see—it points to deteriorating fundamentals. The price has fallen below the stated 52-week range low of ₹185.35; that could simply be Mr. Market's pessimism, but it could also be a value trap. A 1.21% dividend is small consolation. I would not buy today. I need evidence that the industrial cycle has turned, the quarterly losses close, and the balance sheet is sound. Until then, this is a cyclical stock on a downward slide, not a compounder. If the business returns to profitability and book value remains protected, I may revisit; but for now, patience is better than conviction.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer